Michael Saridakis, DO
Family Medicine · Broadview Heights, OHNPI 1164462875
Payments from drug & device makers
Across 421 payments — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$866
- Novo Nordisk$544
- AstraZeneca$463
- Amgen$432
- Biohaven Pharmaceutical Holding Company Ltd.$420
- Pfizer$356
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,60099%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $866 |
| Novo Nordisk | 48 | $544 |
| AstraZeneca | 26 | $463 |
| Amgen | 32 | $432 |
| Biohaven Pharmaceutical Holding Company Ltd. | 41 | $420 |
| Pfizer | 28 | $356 |
| GSK | 25 | $310 |
| Lilly USA, LLC | 24 | $297 |
| Boehringer Ingelheim | 24 | $274 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $259 |
| Johnson & Johnson | 17 | $229 |
| Amarin Pharma, Inc. | 8 | $122 |
| Sunovion Pharmaceuticals Inc. | 6 | $109 |
| Astellas Pharma US Inc | 6 | $107 |
| Sanofi-aventis U.S. LLC | 5 | $102 |
| Abbott | 4 | $80 |
| Merck | 6 | $74 |
| Bayer | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Novartis | 3 | $43 |
| Ironwood Pharmaceuticals, Inc | 3 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Lundbeck LLC | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Atricure, Inc. | 1 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$119
How this compares
$5,644 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 130 | $122,918 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $93,899 |
| MounjaroTirzepatide | 90 | $93,482 |
| EliquisApixaban | 46 | $66,178 |
| JanuviaSitagliptin Phosphate | 66 | $61,964 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $33,268 |
| TrulicityDulaglutide | 17 | $23,516 |
| OzempicSemaglutide | 11 | $21,478 |
| ProliaDenosumab | 12 | $20,978 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $15,329 |
| FarxigaDapagliflozin Propanediol | 17 | $15,299 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $14,911 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $8,513 |
| VascepaIcosapent Ethyl | 14 | $7,609 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $274 | $138,247160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $297 | $116,998107 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $101,477134 claims |
| PfizerEliquis | $356 | $66,17846 claims |
| MerckJanuvia | $74 | $61,96466 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $102 | $35,46739 claims |
| Novo NordiskOzempic | $544 | $21,47811 claims |
| AmgenProlia | $432 | $20,97812 claims |
| AstraZenecaFarxiga, Symbicort | $463 | $20,37229 claims |
| Johnson & JohnsonXarelto | $229 | $6,91213 claims |
| AbbVieSynthroid | $866 | $1,87467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Broadview Heights
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.